Drugs / Astragalus Polysaccharides
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 23 trials | ||||||
| Phase 2 | NCT03611712 | Feb 2019 → Feb 2023 | esophageal cancer | PhytoHealth Corporation | Completed | No outcome recorded |
| Phase 2 | NCT03314805 | Mar 2018 → May 2021 | neutropenia | PhytoHealth Corporation | Completed | No outcome recorded |
| Phase 2 | NCT01720563 | Dec 2012 → Apr 2014 | — | PhytoHealth Corporation | Terminated | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT01720550 | Nov 2012 → Jun 2017 | myalgic encephalomeyelitis/chronic fatigue syndrome | PhytoHealth Corporation | Completed | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT02740959 | Mar 2016 → May 2017 | myalgic encephalomeyelitis/chronic fatigue syndrome | Taipei Medical University | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Astragalus polysaccharides | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03314805 ↗ |
| Known as | PG2 | “This study aimed to evaluate the effect of Astragalus polysaccharides (PG2) on reducing chemotherapy-induced fatigue (CIF) and toxicity, thereby encouraging compliance to chemotherapy.” PMID 39465324 ↗ Oct 2024 |
| Route | Intravenous | “via i.v. infusion” NCT01720563 ↗ |